Cargando…
IL4I1-driven AHR signature: a new avenue for cancer therapy
Autores principales: | Wang, Zuli, Li, Tiansheng, Mao, Chao, Liu, Wenliang, Tao, Yongguang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946875/ https://www.ncbi.nlm.nih.gov/pubmed/33692337 http://dx.doi.org/10.1038/s41392-021-00529-z |
Ejemplares similares
-
Ketogenic diet: new avenues to overcome colorectal cancer
por: Xiang, Yuancai, et al.
Publicado: (2022) -
Macrophages assemble! But do they need IL‐4R during schistosomiasis?
por: Rückerl, Dominik, et al.
Publicado: (2019) -
SARS-CoV-2-induced lung pathology: AHR as a candidate therapeutic target
por: Giovannoni, Federico, et al.
Publicado: (2020) -
A novel mechanism of ferroptosis surveillance offers promising therapeutic avenues for breast and prostate cancers
por: Xu, Rongyang, et al.
Publicado: (2023) -
Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation
por: Li, Tiansheng, et al.
Publicado: (2020)